^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | samotolisib (LY3023414) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
Excerpt:
LY3023414 (LY)...Durable partial response according to RECIST was observed in an endometrial cancer patient harboring PIK3R1 and PTEN mutations and 22 additional patients (47%) had stable disease as their best response.
Trial ID:
